- In August 2026, Sysmex Corporation raised its consolidated earnings guidance for the six months ended September 30, 2026 and the full year to March 31, 2027, lifting expected net sales to ¥265,000 million and ¥545,000 million respectively, alongside higher operating profit and profit attributable to owners of the parent.
- The upgraded outlook, driven mainly by stronger hematology instrument sales in the Americas and a weaker yen than previously assumed, highlights how regional demand and currency shifts are feeding directly into Sysmex’s near‑term profitability expectations.
- We’ll now examine how this guidance upgrade, underpinned by stronger Americas hematology demand, affects Sysmex’s broader investment narrative and risk balance.
AI is about to change healthcare. These 7 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
Sysmex Investment Narrative Recap
To own Sysmex, you need to believe in steady global demand for diagnostic testing, supported by a broad installed base in hematology and adjacent areas. The upgraded earnings guidance reinforces the short term catalyst of stronger Americas hematology demand, while also amplifying the key near term risk that higher profitability is currently helped by a weaker yen and may remain sensitive to currency and regional mix.
Among recent developments, the ongoing share buyback program, with over 21 million shares repurchased under the March 2026 authorization, is highly relevant. It sits alongside the guidance upgrade to shape the near term story, as both earnings expectations and share count assumptions feed into how you might think about per share profitability and Sysmex’s effort to rebuild investor confidence after prior impairments and underperformance.
Yet behind the upgraded guidance, investors should still be watching how policy pressure in China could affect test volumes and margins...
Read the full narrative on Sysmex (it's free!)
Sysmex's narrative projects ¥597.8 billion revenue and ¥57.0 billion earnings by 2029. This requires 6.1% yearly revenue growth and an earnings increase of about ¥21.5 billion from ¥35.5 billion today.
Uncover how Sysmex's forecasts yield a ¥1733 fair value, a 12% downside to its current price.
Exploring Other Perspectives
Some of the lowest ranked analysts were assuming around ¥564,700 million of revenue and ¥46,600 million of earnings by 2029, which reflects a more cautious view on margins and cost pressures compared with the current guidance uplift. This more pessimistic camp, especially around tariffs and logistics costs, shows how differently you and other investors might read the same set of pre upgrade numbers, and how this new guidance could prompt a rethink of those assumptions.
Explore 3 other fair value estimates on Sysmex - why the stock might be worth as much as ¥1800!
Reach Your Own Conclusion
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Sysmex research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Sysmex research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Sysmex's overall financial health at a glance.
Want Some Alternatives?
Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:
- Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- Find 19 companies with promising cash flow potential yet trading below their fair value.
- This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com